PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results

PAVmed posts higher cash, Medicare revenue, and clinical progress but remains unprofitable.

What the company is saying

PAVmed emphasizes a transformative milestone as Lucid Diagnostics secures full Medicare reimbursement for the EsoGuard Esophageal DNA Test, highlighting the near-term revenue potential from at-risk Medicare beneficiaries. The company frames its narrative around operational momentum, citing record test volumes in October and the publication of an 11,991-patient EsoGuard study as evidence of scalability and clinical relevance. Veris Health is presented as advancing rapidly, with patient enrollment at OSU-The James nearly doubling from July to September and its implantable monitor progressing through a 90-day animal study ahead of an early 2027 FDA submission. Octeris Medical is positioned as ready for clinical testing, with regulatory engagement and a University of North Carolina validation study scheduled to begin in January 2027. Chairman and CEO Lishan Aklog, M.D., directly links these operational milestones to long-term shareholder value, projecting confidence in the company's multi-subsidiary portfolio. The announcement foregrounds financial transparency, providing detailed GAAP and non-GAAP results, but downplays ongoing net losses and the lack of profitability.

What the data suggests

Lucid Diagnostics recognized $1.2 million in revenue for Q3 2026, performing 2,871 EsoGuard tests, with October test volume exceeding 1,800. The 11,991-patient study establishes EsoGuard as the largest peer-reviewed nonendoscopic esophageal precancer test to date. PAVmed's cash and cash equivalents rose to $8.9 million as of September 30, 2026, from $1.5 million at year-end 2025, with restricted cash increasing from $0.3 million to $5.3 million. Operating expenses for Q3 were $6.8 million, including $1.0 million in stock-based compensation, and net operating expenses were $5.6 million. The company reported a non-GAAP adjusted net loss of $1.2 million, or $(0.19) per share, while the GAAP net loss attributable to common stockholders was $(11.8) million for the quarter. For the nine months ended September 30, 2026, total revenue was $96,000 and net income (loss) as reported was $(17.1) million. Veris Health's clinical rollout and device development are progressing, but no specific patient enrollment numbers are disclosed. Octeris' clinical and regulatory milestones are described, but without quantitative evidence of readiness. The financial disclosures are detailed, but operational claims about market size and access expansion lack supporting data.

Analysis

The announcement's tone is upbeat, highlighting operational milestones such as Medicare reimbursement for Lucid's EsoGuard test, record test volumes, and progress on clinical and regulatory fronts for subsidiaries. These realised achievements are supported by concrete financial data: $1.2 million in Q3 revenue, increased cash position, and detailed expense breakdowns. However, some claims—such as the expansion of access to 50% of 30 million at-risk patients and Veris Health's 'nearly doubled' enrollment—are not substantiated with specific numbers, inflating the narrative. Forward-looking statements about FDA submissions and clinical study enrollments are present but limited in number and are tied to near-term milestones (early 2027). The company remains unprofitable, with high operating expenses and net losses, but the financial disclosures are transparent. Overall, the narrative is somewhat inflated by unquantified market opportunity and operational growth claims, but the core progress is real and measurable.

Risk flags

• ●PAVmed remains unprofitable, with a GAAP net loss attributable to common stockholders of $(11.8) million for Q3 2026 and $(24.2) million for the nine months ended September 30, 2026. Sustained losses raise questions about the company's ability to achieve profitability without further dilution or capital raises.
• ●Although cash and cash equivalents increased to $8.9 million, $5.3 million is restricted, limiting immediate liquidity. High operating expenses ($6.8 million in Q3) could quickly erode available cash if revenue growth stalls or reimbursement is delayed.
• ●Operational claims regarding market opportunity and access expansion are not supported by specific data on actual penetration or patient numbers, making it difficult to assess the scale and pace of commercial adoption.
• ●Key clinical and regulatory milestones for Veris Health and Octeris are projected for early 2027, but successful FDA submissions and clinical validation are not guaranteed. Delays or negative outcomes could materially impact future value.
• ●Stock-based compensation remains a significant expense ($1.0 million in Q3), potentially leading to further dilution if the company continues to rely on equity-based incentives.

Bottom line

PAVmed's Q3 update demonstrates real operational progress, with Lucid Diagnostics now receiving Medicare reimbursement for EsoGuard and achieving record test volumes, translating into $1.2 million in quarterly revenue. The company's cash position has improved substantially, but restricted cash limits immediate flexibility, and high operating expenses continue to drive significant net losses. While Veris Health and Octeris are advancing toward regulatory and clinical milestones, these value inflection points are still several months away and carry execution risk. The company's narrative is supported by detailed financial reporting, but some operational growth claims lack quantitative backing. Investors should focus on the sustainability of revenue growth, the pace of clinical and regulatory progress, and the company's ability to manage cash burn. The most important takeaway is that Medicare reimbursement is now a reality, but profitability and broad commercial adoption remain unproven.

Announcement summary

(NASDAQ:PAVM) PAVmed Inc. provided a business update and reported financial results for the third quarter ended September 30, 2026. Lucid Diagnostics (NASDAQ:LUCD), a subsidiary, began receiving Medicare payments for the EsoGuard® Esophageal DNA Test in October, submitting claims for tests performed at its Texas laboratory to Novitas, the Medicare Administrative Contractor, and receiving payments at the established Clinical Laboratory Fee Schedule rate. Lucid focused commercial efforts on expanding EsoGuard access among at-risk Medicare beneficiaries, who represent approximately 50% of the 30 million patients recommended for esophageal precancer testing by professional society guidelines. Lucid announced publication of an 11,991-patient real-world EsoGuard study in Diagnostics, the largest peer-reviewed study of nonendoscopic esophageal precancer testing to date, demonstrating the efficiency and scalability of the EsoCheck® Esophageal Cell Collection Device. Lucid performed 2,871 EsoGuard tests and recognized revenue of $1.2 million in Q3 2026, with October being a record month for test volume at over 1,800 tests. Veris Health, another subsidiary, saw monthly patient enrollment at OSU-The James nearly double from July to September as the commercial phase accelerated and the clinical rollout expanded. Veris achieved design freeze for its implantable physiological monitor and initiated a 90-day GLP animal study in October, keeping the device on track for an early 2027 FDA 510(k) submission. PAVmed held an initial meeting with the FDA on PortIO in late October, with an in-person pre-submission meeting scheduled for January 2027. Octeris Medical completed its next-generation multimodal endoscopic imaging probe, ready for clinical testing, and expects to submit its initial FDA pre-submission package this month, with enrollment in the University of North Carolina clinical validation study expected to begin in January 2027. For the three months ended September 30, 2026, PAVmed reported operating expenses of $6.8 million, including $1.0 million in stock-based compensation expenses. Non-GAAP adjusted net loss was approximately $1.2 million or $(0.19) per common share. As of September 30, 2026, PAVmed had cash and cash equivalents of $8.9 million, including restricted cash of $5.3 million, compared to $1.5 million, including $0.3 million of restricted cash, as of December 31, 2025. For the three months ended September 30, 2026, revenue was $41, operating expenses were $6,768,000, other (income) expense, net was $6,308,000, net (income) loss was $13,035,000, net income (loss) attributable to common stockholders was $(11,752,000), preferred stock dividends and deemed dividends were $97,000, and net income (loss) as reported was $(11,655,000). For the nine months ended September 30, 2026, revenue was $96,000, operating expenses were $21,879,000, other (income) expense, net was $(1,087,000), net (income) loss was $20,696,000, net income (loss) attributable to common stockholders was $(24,219,000), preferred stock dividends and deemed dividends were $7,120,000, and net income (loss) as reported was $(17,099,000). Non-GAAP adjusted (loss) for the three months ended September 30, 2026 was $(1,240,000), and for the nine months ended September 30, 2026 was $(4,759,000). Non-GAAP shares outstanding, basic and diluted, were 6,640,000 for the three months ended September 30, 2026. Non-GAAP adjusted (loss) income per share, basic and diluted, was $(0.19) for the three months ended September 30, 2026. Net operating expenses for the three months ended September 30, 2026 were $5,642,000. Cost of revenue for the three months ended September 30, 2026 was $158,000. Sales and marketing expenses for the three months ended September 30, 2026 were $206,000. General and administrative expenses for the three months ended September 30, 2026 were $4,482,000. Research and development expenses for the three months ended September 30, 2026 were $1,922,000.

Disagree with this article?